XML 17 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Income Statement [Abstract]    
Technology development and licensing revenue $ 500,000 $ 500,000
Operating expenses:    
Research and development 11,865,523 13,078,710
General and administrative 9,699,521 5,889,722
Total operating expenses 21,565,044 18,968,432
Loss from operations (21,065,044) (18,468,432)
Other income (expense):    
Gain from change in earn-out milestone liability 3,630,861 649,701
Impairment of in-process research and development (4,510,000) (2,520,000)
Investment income, net 353,682 26,041
Interest expense (712,025) (91,756)
Other income 52 2,270
Total other expense (1,237,430) (1,933,744)
Net loss before income tax benefit (22,302,474) (20,402,176)
Income tax benefit 10,419,115
Net loss (11,883,359) (20,402,176)
Deemed dividend related to warrant modification (345,685)
Net loss attributable to common shareholders $ (11,883,359) $ (20,747,861)
Net loss attributable to common shareholders per common share - basic and diluted $ (0.68) $ (2.72)
Weighted average common shares outstanding - basic and diluted 17,582,879 7,627,210